Qilu Pharmaceutical Donates RMB 100 Million to China Science and Technology Development Foundation to Advance Innovation

Sep 06, 2025 09:05 CST Updated 09:05

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Following the strategic cooperation agreement with the National Natural Science Foundation of China, Qilu Pharmaceutical Co., Ltd. has embarked on another journey towards scientific and technological innovation development.Continuation Chapter。

On September 4, Qilu Pharmaceutical Co., Ltd. formally signed a strategic cooperation agreement with the China Science and Technology Development Foundation, which is affiliated with the China Association for Science and Technology (CAST), in Beijing. Qilu Pharmaceutical donated 100 million yuan to the China Science and Technology Development Foundation, strongly supporting public welfare initiatives such as the development of young scientific talents, science popularization, and international exchanges. Feng Shentong, the Party Leadership Group's Deputy Secretary, Vice Chairman, and Secretary of the Secretariat of CAST, attended the signing ceremony and delivered a speech.Vice President of Qilu Pharmaceutical Group、Chairman Minghui Zhang of Qilu Pharmaceutical Co., Ltd.，Wu Gang, Vice General Manager of Qilu Pharmaceutical Co., Ltd., attended the signing ceremony.

Feng Shenhong expressed gratitude to Qilu Pharmaceutical for supporting the development of China's scientific and technological endeavors. In his speech, he noted that this collaboration represents a vivid practice in promoting the deep integration of innovation and industrial chains, serving a tech-powered and healthy China. He hopes this partnership will fully leverage each party’s strengths and make active contributions in talent cultivation, scientific research, result transformation, and science popularization. He stated that Qilu Pharmaceutical, as an outstanding representative of private pharmaceutical enterprises, is committed to public health and has deeply invested in innovative drug development, making it a core force in pharmaceutical science and technology innovation. This signing represents a significant opportunity to advance the deep integration of innovation and industrial chains. He hopes both parties will share a common vision and together create a model of science and technology empowering industrial development.

Zhang MinghuiIn the speechQilu Pharmaceutical Co., Ltd. stated that it always adheres to innovation-driven development and focuses on technology."Four Orientations," adhering to a patient-centered approach, pursuing "innovation with warmth in science and technology," has established six major R&D platforms linked between China and the U.S., with R&D investment intensity continuously maintained at over 11% for many years, providing more high-quality medicines produced in China that are accessible and affordable for Chinese citizens.

Currently, Qilu Pharmaceutical's life and health products have been cumulatively launched on the market.More than 320 products, achieving "full coverage" of medicine supply from head to toe. Three Class 1 innovative drugs launched, 79 products approved as the first (exclusive) in China, and over 80 innovative drug projects currently under development. This collaboration will further enhance the company’s innovation capabilities and help address challenges in the biopharmaceutical field.

This strategic cooperation explores a new model of integrating technology philanthropy with industrial innovation. Through the efficient linkage between the public welfare platform of the China Science Development Foundation and the industrial strength of enterprises, it will bring significant benefits to China.Biopharmaceutical IndustryHigh QualityInject New Momentum into Development。

Song Jun, Chairman of the China Science and Technology Development Foundation, Organization and Personnel Department of the China Association for Science and Technology, Department of Science and Technology Innovation, Department of Science and Technology PopularizationAndQilu Pharmaceutical Co., Ltd.PersonJointly attended the signing ceremony。